Protein Kinase Cα Phosphorylates a Novel Argininosuccinate Synthase Site at Serine 328 during Calcium-dependent Stimulation of Endothelial Nitric-oxide Synthase in Vascular Endothelial Cells by Haines, Ricci J. et al.
Protein Kinase C Phosphorylates a Novel Argininosuccinate
Synthase Site at Serine 328 during Calcium-dependent
Stimulation of Endothelial Nitric-oxide Synthase in Vascular
Endothelial Cells*
Received for publication, May 4, 2012, and in revised form, June 11, 2012 Published, JBC Papers in Press, June 13, 2012, DOI 10.1074/jbc.M112.378794
Ricci J. Haines‡, Karen D. Corbin§, Laura C. Pendleton‡, and Duane C. Eichler‡1
From the ‡Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida 33612 and
the §Nutrition Research Institute and Department of Nutrition, University of North Carolina at Chapel Hill,
Kannapolis, North Carolina 28081
Background:Argininosuccinate synthase (AS) is critical for endothelial nitric oxide production, yet little is known about its
regulation.
Results: AS Ser-328 phosphorylation increased with calcium stimulation and decreased with PKC interference.
Conclusion: PKC phosphorylates AS at Ser-328 under calcium-dependent stimulatory conditions to support nitric oxide
production.
Significance: Knowledge of how AS is regulated is essential in understanding nitric oxide homeostasis.
Endothelial nitric-oxide synthase (eNOS) utilizes L-arginine
as its principal substrate, converting it to L-citrulline and nitric
oxide (NO). L-Citrulline is recycled to L-arginine by two
enzymes, argininosuccinate synthase (AS) and argininosucci-
nate lyase, providing the substrate arginine for eNOS and NO
production in endothelial cells. Together, these three enzymes,
eNOS, AS, and argininosuccinate lyase, make up the citrul-
line-NO cycle. Although AS catalyzes the rate-limiting step in
NO production, little is known about the regulation of AS in
endothelial cells beyond the level of transcription. In this study,
we showed that AS Ser-328 phosphorylation was coordinately
regulated with eNOS Ser-1179 phosphorylation when bovine
aortic endothelial cells were stimulated by either a calcium
ionophore or thapsigargin to produce NO. Furthermore, using
in vitro kinase assay, kinase inhibition studies, as well as protein
kinase C (PKC) knockdown experiments, we demonstrate
that the calcium-dependent phosphorylation of AS Ser-328 is
mediated by PKC. Collectively, these findings suggest that
phosphorylation of AS at Ser-328 is regulated in accordance
with the calcium-dependent regulation of eNOS under condi-
tions that promote NO production and are in keeping with the
rate-limiting role of AS in the citrulline-NO cycle of vascular
endothelial cells.
Nitric oxide (NO) production is strictly regulated in vascular
endothelial cells. Impairment of this control is associated with
risk factors that compromise endothelial function. Arginine
directed to eNOS2 for purposes of NO production is main-
tained by the recycling of citrulline to arginine, creating a dis-
tinct pool of arginine in endothelial cells (1–4). This intracel-
lular arginine pool that is sequestered from the bulk cytosolic
arginine is generated through the action of the arginine recy-
cling enzymes argininosuccinate synthase (AS) and arginino-
succinate lyase, where catalysis by AS is rate-limiting for NO
production in endothelial cells (1).
Because the endothelium represents a unique environment
under the continuous influence of signaling cascades that inte-
grate responses to physiologic cues, it was logical to propose
that acute or immediate regulation of AS would be necessary to
accommodate regulatory responses already known for eNOS.
For example, VEGF and insulin signaling have been shown to
coordinately regulate two phosphorylation sites of eNOS,
increasing phosphorylation at Ser-1179 and decreasing phos-
phorylation at Thr-497 to effect an overall increase in eNOS
activity (6). This change in eNOS phosphorylation that results
from either VEGF or insulin signaling is mediated largely by
calcium-independent kinases, such as Akt (7).
Despite the fact that relatively recent studies have shown that
AS is a phospho-protein (8, 9), no physiologically relevant phos-
phorylation sites have been reported. In 2008, an automated
phospho-proteome analysis revealed that AS is phosphorylated
at serine 352 in HeLa cells, but the physiologic significance was
not established (9). Later that same year, Corbin et al. (8) also
demonstrated that AS was a phospho-protein and that VEGF
stimulation of NO production affected the phosphorylation of
AS via a PKA pathway, but no phosphorylation site was identi-
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Ser-328 occurs in response to the calcium-dependent activa-
tion of eNOS and is mediated by the  isotype of PKC (PKC).
EXPERIMENTAL PROCEDURES
Cell Culture—BAECs were isolated from whole bovine aorta
as described in Ref. 10 with modifications. Briefly, aortas were
harvested andwashedwith PBSwithoutmagnesiumor calcium
to remove blood, and lumenal surfaces were exposed by longi-
tudinal dissection followed by incubationwith 0.1% collagenase
for 10 min. Endothelial cell isolation was achieved by rolling
sterile swabs across the surface and then releasing cells by twirl-
ing swabs in 5 ml of enriched Dulbecco’s modified Eagle’s
medium (DMEM, 1 g/liter glucose, Invitrogen) containing 10%
FBS (HyClone) with 100 IU/ml penicillin and streptomycin and
250 ng/ml amphotericin B (Cellgro) in 15-ml conical tubes.
Cells were pelleted, resuspended in 6 ml of DMEM  10% FBS,
and plated in 25-cm2 treated cell culture flasks. Authentication
of isolation of endothelial cells in culturewas confirmed by flow
cytometry.
Prior to treatment, confluent BAECs (between passages 3
and 9) were serum-starved for 16 h in DMEM (1 g/liter glucose,
minus phenol red, Invitrogen) supplemented with 0.1% BSA
and 1mM glutamine. Treatments included incubation with 100
nM insulin (Sigma), 100 ng/ml VEGF (R&D Systems), 0.5 M
calcium ionophore A23187 (Sigma), 10 M bradykinin (Sigma),
42 M rottlerin, or 2.5 M bisindolylmaleimide I (Sigma) for
PKC inhibition or 50 M BAPTA-AM (Calbiochem). Incuba-
tion times are indicated in the figure legends. Controls were
treated with serum starvation media only.
Generation of AS Variants and Transient Transfections—AS
cDNAwas cloned into pcDNA 3.1/V5-His, B expression vector
(Invitrogen). The AS construct was then subjected to site-di-
rectedmutagenesis via theQuikChange kit (Stratagene) per the
manufacturer’s instructions. Briefly, Ser-328 was mutated to
alanine to mimic a nonphosphorylated state and to aspartic
acid to mimic a constitutively phosphorylated state. Primers
used for S328A mutation were sense: ACGGGTTTCTGGCA-
CGCGCCCGAGTGTGAATTT and antisense: AAATTCAC-
ACTCGGGCGCGTGCCAGAAACCCGT. Primers used for
S328D mutation were sense: ACGGGTTTCTGGCACGACC-
CCGAGTGTGAATTT and antisense: AAATTCACACTCG-
GGGTCGTGCCAGAAACCCGT. Experimental plasmids (1
g DNA/well of a 6-well dish) were transiently transfected into
BAECs using Lipofectamine 2000 (Invitrogen) in serum-free
Opti-MEM I (Invitrogen). After 4 h, mediumwas replaced with
DMEM containing 10% serum, and cells were cultured for 6 or
24 h. Cells were stimulated with calcium ionophore A23187
and sodium orthovanadate for 4 h, and then culture medium
was assayed for NO production via the 2,3-diaminonaphtha-
lene (DAN) assay.
Mass Spectrometry Analysis—BAECs transiently transfected
with AS were incubated for 24 h, serum-starved for 16 h, and
treatedwith 10Mbradykinin or 50 nM okadaic acid for 30min.
Overexpressed AS was purified by its fused His6 tag using nick-
el-nitrilotriacetic acid-agarose magnetic beads (Qiagen). Pro-
teins were separated by SDS-PAGE to identify the AS band (51
kDa). A duplicate gel was run to confirm expression of the AS
plasmid byWestern blot. Gel bands of interestwere excised and
destained. The protein disulfides were reduced with triscar-
boxyethylphosphine, and the cysteines were alkylated with
iodoacetamide. In-gel trypsin digestion was used for proteoly-
sis. Nanoflow reverse phase liquid chromatography was used to
separate the peptides by hydrophobicity (LC Packings, Dionex,
Sunnyvale, CA). Online detection was accomplished with an
electrospray linear ion trap mass spectrometer (LTQ, Thermo
Scientific). Tandem mass spectra were assigned to peptide
sequences using Mascot and SEQUEST database search algo-
rithms. Sequence assignments were validated by manual
inspection of the data.
Argininosuccinate Synthase Phospho-serine Ser-328 Specific
Antibody—A phospho-specific antibody against Ser(P)-328 AS
was generated by 21st Century Biochemicals using the phos-
pho-peptide AS sequence 322–335: RR-Ahx-YGFWH[pS]-
PECEFVR-amide (where pS indicates phospho-serine). The
phospho-AS antibody specificity was determined by perform-
ing phospho-peptide competition and immunoprecipitation,
followed by Western blotting.
Western Blot Analysis—BAECs were lysed in radio immuno-
precipitation assay buffer supplemented with protease and
phosphatase inhibitors (Pierce) followed by scraping for collec-
tion. Whole cell lysates were clarified, and total protein was
quantitated using the BCA protein assay (Pierce). Equal
amounts (20 g) of protein were resolved on 4–15% Tris-HCl
TGX precast gels (Bio-Rad) and blotted onto Immobilon-P
polyvinylidene difluoride membranes. Western blotting was
performed as described previously (11). Membranes were
blocked in 100% StartingBlock (Pierce) and incubated with pri-
mary antibody, 1:2500 anti-AS (BD Transduction Laborato-
ries), in 20% StartingBlock. Secondary antibody used was per-
oxidase-conjugated goat anti-mouse or anti-rabbit IgG
(Jackson ImmunoResearch Laboratories) at 1:50,000 dilution.
Blots were visualized by chemiluminescence using West Pico
reagent (Pierce) and exposed to film. Band intensities were
quantitated using the Quantity-One software (Bio-Rad).
Nitric Oxide Determinations—Nitrite was measured in the
medium as an indicator of cellular NO using the fluorescent
DAN (Sigma) assay as described previously (12). Reactions
were carried out in 96-well black plates, and fluorescence was
read on a BMG FLUOstar Galaxy spectrofluorometer plate
reader exciting at 360 nm and detecting emission at 405 nm.
Data are described as pmol of nitrite per microgram protein.
PKC Knockdown Assay—BAECs, 90% confluent, were
transfected for 48 h with dicer substrate siRNA (DsiRNA)
directed against the fifth exon of PKC (Integrated DNATech-
nologies) using Lipofectamine 2000 (Invitrogen) performed as
described previously for AS constructs. The duplex sequence
used to silence the gene expression was the following: 5-CGA-
GGAGCAAGCACAAGUUCAAGAT-3 and 5-AUCUUG-
AACUUGUGCUUGCUCCUCGGG-3. Transfected BAECs
were then treatedwith calcium ionophore (A23187, Sigma) and
lysed followed by Western blotting. Relative amounts of indi-
cated proteins were quantitated as described above.
In Vitro Kinase Assay—Assays were performed as described
by Corbin et al. (8). Briefly, purified recombinant AS was gen-
erated via subcloning bovine AS (NP_776317) into the pET-
28(c) vector (Novagen) and expressed in Escherichia coli. The
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protein was subsequently purified via theHisBind resin per the
manufacturer’s instructions (Novagen). Successful purification
was verified by SDS-PAGE. The positive control used to deter-
mine kinase activity for each kinase contained applicable pep-
tide substrate, whereas negative control contained all compo-
nents except peptide. The addition of [33P]ATP to each
reaction mixture initiated the assays incubated at 30 °C for 30
min. Assay termination was achieved by reaction spotting on
phospho-cellulose P81 plates followed by three washes, and
then radioactivity was read via scintillation counting. Imaged in
vitro kinase reactions were terminated by the addition of sam-
ple buffer and then fractionated on 10% polyacrylamide gels.
RESULTS
Identification of the Argininosuccinate Synthase Ser-328
Phosphorylation Site—To establish biologically significant sites
of phosphorylation in the AS sequence, we carried out a pro-
teomic analyses by applying mass spectrometry (LC-MS/MS)
on overexpressed AS purified from cultured BAECs treated
with bradykinin or okadaic acid (protein phosphatase 2A
(PP2A) and PP1 phosphatase inhibitor). Mass spectrometry
analysis revealed three highly conserved serine/threonine
phosphorylation sites that were distinguished from back-
ground ion signal. These included Thr-131/Ser-134, Ser-180/
Ser-189, and Ser-328 (Fig. 1). The proximity of Thr-131 to Ser-
134 and Ser-180 to Ser-189 made these individual signals
indistinguishable and therefore described as Thr-131/Ser-134
and Ser-180/Ser-189.
Of the sites identified, Ser-328 showed the greatest change in
signal between cells treated with phosphatase inhibitor (oka-
daic acid) and nontreated cells. In addition, Ser-328 showed
substantial change in signal with bradykinin treatment relative
to nontreated control cells (Fig. 1). Furthermore, in silicomod-
eling showed that the most accessible sites for kinase interac-
tion were Thr-131/Ser-134 and Ser-328, whereas Ser-180/Ser-
189 appeared buried near the active site of the enzyme (data not
shown). Based on these results, Ser-328 was selected as being
the strongest candidate for phosphorylation in vivo. Conse-
quently, a phospho-specific antibody directed against Ser(P)-
328 was developed for further investigation (see “Experimental
Procedures”).
Calcium-independent Stimulation of BAECs Decreases Phos-
phorylation at Ser-328—To determine whether phosphoryla-
tion at Ser-328 had physiological significance, changes in Ser-
328 phosphorylation were examined relative to treatment by
physiological cues that alter NOproduction. In particular, both
VEGF and insulin stimulation of NO production were chosen
for two reasons. First, there is evidence that AS phosphoryla-
tion changed in response to VEGF treatment, which was medi-
ated via PKA signaling (8). Second, both VEGF and insulin are
known to stimulate endothelial NO production by promoting
phosphorylation of Ser-1179 of eNOS (13, 14).
As shown in Fig. 2, and consistent with the literature (13), we
found that insulin and VEGF promoted an increase in phos-
phorylation by roughly 50%of eNOS at Ser-1179 (Western blot,
Fig. 2, A and C; densitometry, Fig. 2, B and D), with a corre-
sponding increase in NO production (Fig. 2E). There was also
concomitant decrease in phosphorylation of eNOS at Thr-497
by 40% (Western blot, Fig. 2, A and C; densitometry, Fig. 2, B
and D) (15–17). Surprisingly, phosphorylation at Ser-328 was
markedly reduced by treatment with either VEGF (85%) or
insulin (40%) (Western blot, Fig. 2, A and C; densitometry, Fig.
2, B and D).
Calcium-dependent Stimulation of BAECs Increases Phos-
phorylation at Ser-328—Insulin and VEGF mediate eNOS
phosphorylation at Ser-1179 via the PI3K/Akt pathway, which
is largely calcium-independent (18–20). Because calcium-in-
dependent signaling mediated by either insulin or VEGF pro-
moted the apparent dephosphorylation of AS Ser-328, we then
questioned whether phosphorylation at Ser-328 was involved
with calcium-dependent signaling. To initially explore this
question, site-directed mutagenesis analysis was carried out.
Three constructs were used, one containingwild type (WT)AS,
one containing an Ala substitution for Ser-328 (phospho-null),
and one containing an Asp substitution for Ser-328 (phospho-
mimetic). As shown in Fig. 3A, the overexpression of phospho-
mimetic S328DAS enhancedNOproduction similar toWTAS
when stimulated with calcium ionophore. Conversely, overex-
pression of phospho-null S328A AS failed to enhance NO pro-
duction in response to the same treatment. Consistent expres-
sion of the constructs is shown by Western blotting (Fig. 3B).
The observation that only S328D overexpression increasedNO
production to the level of WT suggested that phosphorylation
at Ser-328 supports arginine delivery to eNOS under calcium-
dependent stimulatory conditions.
Because these findings were consistent with calcium depen-
dence, experiments were then carried out to determine
whether calcium-dependent changes in Ser-328 could be dem-
onstrated for endogenous AS. For these experiments, BAECs
were treated with either the calcium ionophore, A23187, or the
endoplasmic reticulum ATPase inhibitor, thapsigargin. Both
FIGURE 1. Ser-328 (S328) is an exposed site accessible by kinases and
shows change in phosphorylation relative to treatment. BAECs were tran-
siently transfected with AS expression vector and then treated with 10 M
bradykinin or 50 nM okadaic acid. AS was His tag-purified and then subjected
to SDS-PAGE. The band corresponding to AS was excised and trypsin-di-
gested before tandem mass spectrometry analysis. Results represent one
experiment with samples analyzed in triplicate with S.E. represented by error
bars. NT, nontreated.
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agents are known to promote an intracellular increase in cal-
cium (21) and stimulate NO production. As shown in Fig. 4, A
and B, treatment with either agent promoted phosphorylation
of eNOS at Ser-1179 by nearly 50% with a subsequent decrease
in phosphorylation of eNOS at Thr-497 by 40%, consistent with
reported values (21, 22). However, in this case, treatment with
calcium ionophore or thapsigargin demonstrated an increase in
phosphorylation at AS Ser-328 (60%) (Fig. 4, A and B).
To further substantiate the calcium dependence of AS Ser-
328 phosphorylation, BAECswere treatedwith the intracellular
calcium chelator BAPTA-AM.As expected, calcium ionophore
and thapsigargin rescued phosphorylation at eNOS Ser(P)-
1179 that diminished with BAPTA-AM treatment alone.
Importantly, as shown in Fig. 4A, treatment with 50 M
BAPTA-AM completely abolished phosphorylation at Ser-328,
as well as the phosphorylation at eNOS Ser-1179. Thus, phos-
phorylation of AS Ser-328 appeared to be coordinately regu-
lated with the phosphorylation of eNOS Ser-1179 through cal-
cium-dependent signaling.
To demonstrate physiological relevance, NO measurements
were taken after cells were treated with BAPTA-AM for 30min
followed by stimulation with calcium ionophore A23187 for 20
min. A23187 and thapsigargin significantly increased NO pro-
duction relative to nontreated or BAPTA-AM-treated BAECs
(Fig. 4C). In addition, BAPTA-AM treatment significantly
decreased A23187- or thapsigargin-stimulated NO production
by 2.5- and 2-fold, respectively.
PKC Is Involved in Mediating Ser-328 Phosphorylation in
BAECs—To further elucidate the signaling pathway involved in
the calcium-dependent phosphorylation of AS at Ser-328, a
series of experiments was carried out using kinase inhibitors.
Because the classical PKC isotypes are calcium-dependent
kinases and are not involved in insulin or VEGF signaling (23,
24), we hypothesized that a member of the PKC family may be
involved in the calcium-dependent phosphorylation of AS Ser-
328. To test this hypothesis, non-isotype-specific PKC inhibi-
tion studies were carried out. As a first approach, the effects of
PKC inhibition were directly measured by examining AS Ser-
FIGURE 2. Calcium-independent stimulation of NO production decreased phosphorylation at argininosuccinate synthase Ser-328 (S328). A and C,
BAECs were treated with insulin (Ins) at 100 nM (A) or VEGF at 100 ng/ml (C) for 20 min. Phosphorylation (P) was assayed by Western blotting using phospho-
specific antibodies and reprobed with eNOS and AS specific antibodies. Blots are representative of three separate experiments. NT, nontreated. B and D,
densitometric values represent the percentage of change from nontreated controls normalized to total eNOS or AS, respectively. Densitometric changes are
significant with S.E. represented by error bars (n  3, p  0.05). E, culture medium from BAECs treated with insulin or VEGF was assayed for nitrite with the DAN
assay with S.E. represented by error bars (*, n  3, p  0.05).
FIGURE 3. Overexpressed Ser-328 phospho-null mutation to alanine produced significantly less stimulated NO than WT or phospho-mimetic (S328D).
A, BAECs were transiently transfected with WT, phospho-null serine to alanine 328 (S328A), or phospho-mimetic serine to aspartate (S328D) AS and then
stimulated with 0.5 M calcium ionophore A23187 and 50 M sodium orthovanadate. Results are representative of four different experiments with S.E. noted
by error bars. (*, p  0.05 relative to WT; †, p  0.05 relative to S328D). B, representative Western blot confirming WT, S328A, and S328D overexpression.
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328 phosphorylation. As shown in Fig. 5A and B, treatment of
BAECs with either the PKC inhibitor rottlerin or the PKC
inhibitor bisindolylmaleimide I, followed by stimulation with
calcium ionophore, decreased AS Ser-328 phosphorylation by
60% relative to nontreated controls. These results were taken
to be consistent and supportive of the role of a classical PKC
isotype promoting phosphorylation of AS at Ser-328.
Interestingly, phosphorylation at Thr-497 or Ser-1179 of
eNOS also decreased with treatment of rottlerin by60%, irre-
spective of calcium stimulation. In contrast, when BAECSwere
treated with bisindolylmaleimide I alone, phosphorylation at
Ser-1179 and Thr-497 of eNOS decreased by only 20%. How-
ever, upon calcium stimulation, phosphorylation at eNOS Ser-
1179 increased to levels similar to calcium ionophore treatment
alone.Nevertheless, phosphorylation at Ser-328was unaffected
by calcium in the presence of bisindolylmaleimide I (Fig. 5A).
To demonstrate the physiological relevance of the system in
response to inhibitors, we measured NO production for each
treatment (Fig. 5C). PKC inhibition with bisindolylmaleimide I
has little effect onNOproduction by BAECs; however, rottlerin
significantly reduced calcium ionophore-stimulated NO pro-
duction by over 2-fold. These results suggest that rottlerin may
affect the activity of several kinases, and bisindolylmaleimide I
clearly decreased phosphorylation at eNOS Thr-497 and thus
promoted NO production similar to calcium ionophore alone.
To further examine the potential involvement of other calci-
um-dependent kinases that could phosphorylate Ser-328, addi-
tional kinase inhibition studies were carried out. ERK1/2 was
inhibitedwith PD98059, andCa2/calmodulin-dependent pro-
tein kinase II (CaMKII) was inhibitedwithKN93. In either case,
no inhibitor effect was observed on AS Ser-328 phosphoryla-
tion when BAECs were co-treated with calcium ionophore or
thapsigargin (data not shown). These results suggest that PKC,
but not ERK1/2 or Ca2/calmodulin-dependent protein kinase
II, is responsible for the calcium-stimulated phosphorylation of
AS Ser-328.
Because PKC is a calcium-dependent kinase that has been
shown to be active during calcium-dependent stimulation of
eNOS (25), we sought to determine whether this is the isotype
responsible for phosphorylating Ser-328 of AS. To test this, we
examined the effects of direct knockdown of PKC with
DsiRNA. DsiRNA is different from traditional siRNA used for
gene silencing in that the RNA duplex used to silence not only
mimics dicer products, but is also optimized for dicer process-
ing by the RNA-induced silencing complex (RISC) to result in a
more potent knockdown (26). As shown in Fig. 6, significant
knockdown of PKC was achieved. DsiRNA directed against
PKC allowed for 50 and 75% knockdown at 1 and 5 nM
DsiRNA, respectively. Knockdown of PKC followed by treat-
ment with calcium ionophore showed a decrease in phos-
phorylation of Ser-328 by 50 and 60% with 1 or 5 nM, respec-
tively, and prevented increased phosphorylation in response to
calcium ionophore treatment. Phosphorylation of eNOS at Ser-
1179 was largely unaffected by PKC knockdown under these
FIGURE 4. Calcium-dependent stimulation of NO production increased phosphorylation at argininosuccinate synthase Ser-328. A, Western blot anal-
ysis of changes in phosphorylation (P) relative to 20 min of treatment with calcium ionophore (A23187) and thapsigargin (Thap) in the presence or absence of
intracellular calcium chelator BAPTA-AM. Blots are representative of five separate experiments. B, densitometric values represent the percentage of change
from nontreated (NT) controls normalized to total eNOS or AS, respectively. Densitometric changes are significant with S.E. represented by error bars. C, culture
medium from BAECs treated with calcium ionophore (A23187) and thapsigargin in the presence or absence of BAPTA-AM was assayed for nitrite with the DAN
assay. (n  5, significantly increased from nontreated: *, p  0.05, significantly decreased from A23187 alone ‡, p  0.05, significantly decreased from
thapsigargin alone; †, p  0.05).
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conditions, whereas eNOS Thr-497 dropped 60% when
PKC was knocked down by 80%. These results suggest that
PKC is a kinase that phosphorylates Ser-328 of AS.
PKC Directly Phosphorylates AS—Because an observed
decrease in phosphorylation due to kinase knockdown may be
the result of inhibition of an upstream kinase in a signaling
cascade, a targeted in vitro kinase assaywas performed to deter-
minewhether PKC directly phosphorylatesAS.Akt1was used
as a negative control based on the lack of a consensus Akt phos-
phorylation motif (RXRXX(S/T)) (27) in the AS protein
sequence.
As shown in Fig. 7A, PKC clearly demonstrated the capacity
to phosphorylate AS in vitro. Although there was an increase in
counts above the blank reaction with Akt1, this was below the
threshold considered significant. SDS-PAGE fractionation of
32P-labeled kinase reaction products and visualization by auto-
radiography film exposure confirmed that PKC, but not Akt1,
phosphorylates AS (Fig. 7B).
DISCUSSION
Vascular endothelial NO production is a dynamic and tar-
geted process, where multilevel regulation of eNOS is well
established (28). Because AS is required for NO production, it
was logical to speculate that the post-translational regulation of
AS would play a significant role in maintaining NO homeosta-
sis. Indeed, recent work using mass spectrometry analysis
showed that AS is phosphorylated at site Ser-352 (human
sequence) (9); however, the biological significance of this phos-
phorylation was not defined. In addition, Corbin et al. (8)
showed that phosphorylation of AS was altered in response to
VEGF treatment, yet the phosphorylation site was unknown. In
this study, we demonstrated that AS Ser-328 phosphorylation
supports the calcium-dependent stimulation ofNOproduction
in vascular endothelial cells and is mediated by PKC.
The involvement of AS in catalyzing the rate-limiting step of
the arginine recycling side of the citrulline-NO cycle is critical
in sustaining NO production in endothelial cells (29). Consis-
tent with the established transcriptional co-regulation between
AS and eNOS (30–32), work described in this study, using
Western blot analysis, showed that AS is co-regulated post-
translationally with eNOS under conditions where the stimu-
lation of NO production is dependent on calcium-mediated
signaling. Further studies showed that calcium stimulation of
BAECs overexpressing the phospho-mimetic (S328D) AS
FIGURE 5. Non-isotype-specific inhibition of PKC with 42 M rottlerin or 2.5 M bisindolylmaleimide I decreased phosphorylation (P) at AS Ser-328.
BAECs were pretreated with 42 M rottlerin (Rott) or 2.5 M bisindolylmaleimide I (Bis) for 30 min prior to stimulation with calcium ionophore (A23187) for 20
min. A, representative Western blot of three experiments. B, densitometric values represent the percentage of change from nontreated (NT) controls normal-
ized to total eNOS or AS, respectively. Densitometric changes are significant with S.E. represented by error bars (n  3, p  0.05). C, culture medium from treated
BAECs was assayed for nitrite with the DAN assay. A23187 significantly increased NO production with or without bisindolylmaleimide I (significance relative to
nontreated: *, n  3, p  0.05; significance relative to A23187: ‡, n  3, p  0.05).
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FIGURE 6. Knockdown of PKC decreased phosphorylation (P) at Ser-328 but not eNOS Ser-1179. BAECs were treated with 1 or 5 nM DsiRNA directed
against the fifth exon of PKC and allowed to express for 24 h, followed by stimulation with calcium ionophore A23187 for 20 min, and compared with
nontreated BAECs. A, representative Western blot of three experiments. B, densitometric values represent the percentage of change from nontreated
(NT) controls normalized to total eNOS or AS, respectively. Densitometric changes are significant (except for A2317 effect on PKC expression or 1 nM
DsiRNA treatment on pS1179 eNOS) with S.E. represented by error bars (n  3, p  0.05) (significance relative to nontreated or DsiRNA alone: *, n  3,
p  0.05).
FIGURE 7. PKC, but not Akt, phosphorylate AS in vitro. A, in vitro kinase assays. Gray bars represent the incubation of purified AS minus kinase (Blank). Black
bars represent the incubation of purified AS with the indicated kinase (Kinase). Kinase activity is represented as cpm with error bars representing S.E. (n  3, *,
p  0.05). B, representative autoradiograph of in vitro kinase reactions separated by SDS-PAGE as described in A.
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increased NO production to that of the overexpressedWT AS,
whereas the overexpressed phospho-null (S328A) AS was
unable to support this increase inNOproduction relative to the
WT control (Fig. 3). Moreover, the finding that under basal
conditions both the null and the phospho-mimetic AS mutant
constructs were able to enhance NO production to that of the
wild type construct also verified that both overexpressed AS
mutants were metabolically active (data not shown). Finally,
through kinase inhibitor studies and knockdown analyses, we
were able to establish that the phosphorylation of AS Ser-328
under calcium-mediated stimulation of NO production was
facilitated by PKC.
Considering the essential role that AS plays in NO produc-
tion and the spatial and temporal manner in which eNOS is
regulated by calcium levels, it is not surprising that AS is sus-
ceptible to a regulatory mechanism governed by changes in
calcium. Indeed, the fact that the calcium-independent activa-
tion of eNOS byVEGF or insulin resulted in a decrease in phos-
phorylation at AS Ser-328 further differentiated AS Ser-328
phosphorylation from the calcium-dependent pathway for
eNOS activation.
Previously, our laboratory had shown thatAS resides in cave-
olae with eNOS (33). Because PKC is associated with the
plasma membrane when activated (34), a local functional rela-
tionship between PKC and ASmay be supported. In addition,
it has been reported that changes in intracellular calcium pro-
mote the cytosolic relocalization of eNOS (5). Therefore, it is
also tempting to speculate that the phosphorylation of AS at
Ser-328 may promote cytosolic AS relocalization in a manner
consistent with eNOS in response to calcium-mediated signal-
ing. Thiswould then ensuremaintenance of the functional rela-
tionship between arginine recycling and the translocated
eNOS. Experiments are underway to test this hypothesis.
In summary, these results represent the first demonstration
of a biologically relevant phosphorylation site for AS and are
consistent with previous findings demonstrating the coordi-
nate regulation of eNOS and AS relative to vascular endothelial
NO production. Given the critical role of AS in vascular endo-
thelial NO production and previous work from our laboratory
showing that the overall phosphorylation of AS changes in
response to VEGF treatment (8), these results also suggest that
other sites of phosphorylation are in involved in AS regulation
and that these sites merit further consideration.
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